Analysis of clinical features of pseudohyperaldosteronism induced by posaconazole
WANG Chunjiang, SUN Wei, WU Cuifang, LIU Shikun, LI Zuojun
2022, 17(6):
448-453,466.
Asbtract
(
208 )
PDF (858KB)
(
45
)
References |
Related Articles |
Metrics
Objective To understand the clinical features of posaconazole-induced pseudoaldosteronism (PIPH). Methods We searched Chinese and English databases (as of 2021.6), collected case reports of PIPH, extracted patient-related information, and performed descriptive statistical analysis. Results A total of 12 case reports of posaconazole-induced pseudoaldosteronism were retrieved, involving 32 patients (18 males and 14 females), with a median age of 58 years (6-87). Nine patients used posaconazole mainly for the prevention of invasive fungal diseases, and 23 patients were mainly used for the treatment of invasive fungal diseases (12 cases of coccidioidomycosis, 4 cases of mucor, 3 cases of histoplasmosis, 1 case of aspergillus, 1 case of sporotrichosis). The median time of occurrence of pseudo-aldosteronism was 14 weeks (1.4-225). Only 4 patients developed clinical symptoms (flushing, headache, gynecomastia, fatigue, polyuria, edema). The median plasma concentration of posaconazole was 3.80 μg/mL (0.03-6.4). Nineteen patients had systolic blood pressure >140 mmHg, 15 patients had serum potassium <3.5 mmol/L, and 26 patients had elevated 11-deoxycortisol, 2 patients were normal; 30 patients had reduced or undetectable aldosterone levels; 19 patients had reduced or undetectable renin, 11 patients had renin at the lower limit of normal. After the occurrence of pseudo-aldosteronism, 15 patients discontinued posaconazole or reduced the dose in 14 patients, and continued treatment in 3 patients. Three patients were added with spironolactone, and 7 patients were replaced with other antifungal drugs. After discontinuing posaconazole or reducing the dose, the patient's blood pressure and serum potassium were improved compared with before, and the laboratory indicators gradually returned to normal. Conclusion PIPH can be manifested as hypertension and hypokalemia, 11-deoxycortisol is increased, aldosterone and renin are decreased or undetectable, and the serum concentration of posaconazole is increased. Patients receiving posaconazole treatment should be screened for hypertension and hypokalemia. If abnormalities are found, further endocrine evaluation should be performed.